Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial
Authors:
- Pablo RojoPRPablo Rojo
- Cinta MoraledaCMCinta Moraleda
- Alfredo TagarroATAlfredo Tagarro
- Sara Domínguez-RodríguezSDSara Domínguez-Rodríguez
- Lola Madrid CastilloLCLola Madrid Castillo
- Luis Manuel Prieto TatoLTLuis Manuel Prieto Tato
- Aranzazu Sancho LópezALAranzazu Sancho López
- Olivier MarcyOMOlivier Marcy
- Valeriane LeroyVLValeriane Leroy
- Alessandra NardoneANAlessandra Nardone
- David BurgerDBDavid Burger
Open Access
- 27 June 2022
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-36
Abstract
Background: Pneumonia is the primary cause of death among HIV-infected children in Africa, with mortality rates as high as 35–40% in infants hospitalized with severe pneumonia. Bacterial pathogens and Pneumocystis jirovecii are well known causes of pneumonia-related death, but other important causes such as cytomegalovirus (CMV) and tuberculosis (TB) remain under-recognized and undertreated. The immune response elicited by CMV may be associated with the risk of developing TB and TB disease progression, and CMV may accelerate disease caused both by HIV and TB. Minimally invasive autopsies confirm that CMV and TB are unrecognized causes of death in children with HIV. CMV and TB may also co-infect the same child. The aim of this study is to compare the impact on 15-day and 1-year mortality of empirical treatment against TB and CMV plus standard of care (SoC) versus SoC in HIV-infected infants with severe pneumonia. Methods: This is a Phase II-III, open-label randomized factorial (2 × 2) clinical trial, conducted in six African countries. The trial has four arms. Infants from 28 to 365 days of age HIV-infected and hospitalized with severe pneumonia will be randomized (1:1:1:1) to (i) SoC, (ii) valganciclovir, (iii) TB-T, and (iv) TB-T plus valganciclovir. The primary endpoint of the study is all-cause mortality, focusing on the short-term (up to 15 days) and long-term (up to 1 year) mortality. Secondary endpoints include repeat hospitalization, duration of oxygen therapy during initial admission, severe and notable adverse events, adverse reactions, CMV and TB prevalence at enrolment, TB incidence, CMV viral load reduction, and evaluation of diagnostic tests such as GeneXpert Ultra on fecal and nasopharyngeal aspirate samples and urine TB-LAM. Discussion: Given the challenges in diagnosing CMV and TB in children and results from previous autopsy studies that show high rates of poly-infection in HIV-infected infants with respiratory disease, this study aims to evaluate a new approach including empirical treatment of CMV and TB for this patient population. The potential downsides of empirical treatment of these conditions include toxicity and medication interactions, which will be evaluated with pharmacokinetics sub-studies. Trial registration: ClinicalTrials.gov, NCT03915366, Universal Trial Number U111-1231-4736, Pan African Clinical Trial Registry PACTR201994797961340.Keywords
All Related Versions
Funding Information
- European and Developing Countries Clinical Trials Partnership (RIA2017MC-2013 EMPIRICAL)
This publication has 36 references indexed in Scilit:
- The Immune Response in TuberculosisAnnual Review of Immunology, 2013
- Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral TherapyThe Journal of Infectious Diseases, 2011
- Prevalence and Outcome of Cytomegalovirus-associated Pneumonia in Relation to Human Immunodeficiency Virus InfectionThe Pediatric Infectious Disease Journal, 2011
- CMV pneumonia in HIV‐infected ventilated infantsPediatric Pulmonology, 2010
- Sample size re‐estimation in clinical trialsBiometrical Journal, 2009
- Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsThe Lancet Infectious Diseases, 2008
- Type I Interferon Response to Cytomegalovirus Infection: The Kick-StartCell Host & Microbe, 2008
- Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trialBMJ, 2006
- Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 2006
- Treatment of Cytomegalovirus Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow TransplantsAnnals of Internal Medicine, 1988